Here’s What 30 Minutes of Jump Rope for a Month Did to This Guy’s Body

For his most recent one month physical challenge, Cam Jones (one half of YouTube’s Goal Guys) followed his brother Brendan’s example and set out to jump rope every single day for 30 days. After acquiring a simple speed rope and a 1-pound weighted rope, Cam assigns himself a target of doing 30 minutes each day.… Read More »

Most switches to Descovy PrEP are probably unnecessary and some may be harmful

One in eight PrEP users in Boston switched from the better-established formulation Truvada to the newer Descovy, but only 7% of those switching had a clinical indication for doing so. Moreover, 14% made potentially harmful switches, as Descovy may have a negative effect on body weight and cholesterol. The data come from Fenway Health, a… Read More »

“Investigating Health & Medicine” – Global Investigative Journalism Network

We welcome comments, which users can leave at the end of any of our systematic story reviews or at the end of any of our blog posts. But before leaving a comment, please review these notes about our policy. You are responsible for any comments you leave on this site. This site is primarily a… Read More »

The Latest: Maine CDC: Rural areas need more COVID testing

PORTLAND, Maine — Maine’s rural areas need better access to COVID-19 testing, the head of the state’s Center for Disease Control and Prevention said. The percent positivity rate in some of Maine’s rural counties is much higher than it is in more densely populated areas such as Cumberland County. Federal data show the percent positivity… Read More »

Tessian officially named a 2021 UK’s Best Workplace™ in Tech

London, UK. 30th September 2021 – Human Layer Security company Tessian has been recognized as one of the 2021’s UK’s Best Workplaces™ in Tech. The list, launched this morning, includes 98 organizations which were selected after Great Place to Work® UK analysed the responses of UK-based tech employees via its Trust Index© employee survey. What… Read More »

Despite rough start, Biogen’s Aduhelm should find footing, analysts say. But don’t expect much in 2021

As Biogen’s new Alzheimer’s drug Aduhelm makes headlines nearly every day—many covering the drug’s slower-than-expected uptake—one team of biopharma analysts is lowering its 2021 expectations for the med. Nonetheless, despite the drug sputtering out the gate, the team still sees a multibillion-dollar sales opportunity for the company in Alzheimer’s disease. Writing to investors Wednesday, analysts with RBC Capital Markets… Read More »